Michael J Hanley

14PUBLICATIONS
14CO-AUTHORS
PharmacogenomicsMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Liquid biopsiesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Mar 03, 2025
Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study.

Michael J Hanley, Thomas R Larson, Paul M Diderichsen

|May 24, 2024
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants.

Michael J Hanley, Steven Zhang, Robert Griffin

|Mar 21, 2024
Mobocertinib: Mechanism of action, clinical, and translational science.

Michael J Hanley, D Ross Camidge, Robert J Fram

|Jan 30, 2024
Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.

Michael J Hanley, Karen Rowland Yeo, Meera Tugnait

|Jul 26, 2023
Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor.

Neeraj Gupta, Michael J Hanley, Robert J Griffin

|May 23, 2023
Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study.

Michael J Hanley, Paul Diderichsen, Benjamin Rich

Pageof 3

Frequent Collaborators

13 joint publications

Neeraj Gupta

7 joint publications

Karthik Venkatakrishnan

4 joint publications

Paul M Diderichsen

2 joint publications

Meera Tugnait